Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 42 Lung Neoplasms 18 Melanoma 14 Carcinoma, Hepatocellular 14 Neoplasm Metastasis 13 Esophageal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 9 Breast Neoplasms 8 Head and Neck Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 Rectal Neoplasms 5 Colorectal Neoplasms 5 Stomach Neoplasms 4 Recurrence 4 Neoplasms 4 Carcinoma, Renal Cell 4 Brain Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Small Cell Lung Carcinoma 3 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Cholangiocarcinoma 3 Carcinoma, Transitional Cell 3 Radiation Pneumonitis 2 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oropharyngeal Neoplasms 2

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Muscle-Invasive Bladder Carcinoma × Immunotherapy × Clear all

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡